ORMP
Oramed Pharmaceuticals Inc. (NASDAQ)
Healthcare — Biotechnology
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Strong Buy
1 analysts
$4.61
$-0.20 (-4.16%)
Target:
$6.25
(35.6%)
Sign in to add ORMP to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $188.67M |
| P/E Ratio (TTM) | 1.77 |
| Forward P/E | -57.63 |
| EPS (TTM) | $2.60 |
| Dividend Yield | 5.43% |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | 58.16% |
| Debt/Equity | 0.32 |
| Recommendation | Strong Buy |
| Analyst Target | $6.25 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 70.4 |
| Beta | 1.24 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $5.19 |
| 52-Week Low | $1.98 |
| 50-Day Avg | $4.08 |
| 200-Day Avg | $3.26 |
| Avg Volume | 280.7K |
| Volume | $1.02M |
Performance Analysis
BULLISHORMP shows predominantly bullish signals based on its fundamentals and technicals.
+
Showing strength at 82% of its 52-week range.
-
RSI at 70.4 indicates overbought conditions — a pullback may be due.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
P/E of 1.8 suggests the stock may be undervalued.
+
Wall Street consensus is "Strong Buy" from 1 analysts.
+
Average analyst target of $6.25 implies 35.6% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:25 UTC
Back to Screener Export Report